The U.S. Food and Drug Administration (FDA) has approved the CT LUCIA 621P Monofocal IOL from ZEISS, an aspheric, monofocal, single-piece C-loop IOL. 

The IOL features the patented ZEISS Optic (ZO) Asphericity Concept, which is designed to compensate for a wide range of spherical aberrations and at the same time optimise visual outcomes in the event of potential decentration and lens misalignments.

Sri Ganesh, MD, chairman and managing director of Nethradhama Super Speciality Eye Hospital, Bangalore (India), said: “This is my standard, go-to monofocal lens. It’s one we use routinely in our practice and even for complex cases. Since it’s a preloaded lens that is easy to use, it’s very predictable. And the refractive stability is reliable from 15-day post-op to three months, or even one year out.”

The CT LUCIA 621P Monofocal IOL is a key element of the ZEISS cataract workflow solution portfolio enabling surgeons to deliver optimised visual outcomes for cataract patients. Along with the patented ZEISS Optic (ZO) Asphericity Concept, the IOL comes in a fully preloaded injector for an intuitive, smooth, and controlled injection. Additionally, the architecture of the IOL is designed to enable easy centring while maximising direct capsular contact, thus ensuring stability and supporting a consistent position in the bag.